Loading clinical trials...
Loading clinical trials...
Impact of a Cream Containing Madecassoside and 5 % Panthenol in Post Photodynamic Therapy Procedure for Actinic Keratosis: A Randomized, Controlled Trial
Premalignant AKs are highly frequent in the light-skinned populations with an increasing incidence. PDT is considered a well-establish treatment for these lesions, and therefore it is essential to achieve an optimal and effective treatment as possible. The present study proposes a new post-treatment modality with application of an anti-inflammatory moisturizer Cicaplast Baume B5+ to the treated areas that may improve the overall patient satisfaction and minimize the local skin reactions. Treatment regime consists of two daily applications of Cicaplast Baume B5+ for 14 days, and this regime is not associated with increased risk of systemic AEs or serious events.
Age
18 - 100 years
Sex
ALL
Healthy Volunteers
No
Bispebjerg Hospital
Copenhagen NV, Denmark
Start Date
September 27, 2023
Primary Completion Date
February 29, 2024
Completion Date
February 29, 2024
Last Updated
May 8, 2024
20
ACTUAL participants
Cream containing madecassoside and 5 % panthenol
OTHER
Daylight PDT
OTHER
Lead Sponsor
Merete Haedersdal
Collaborators
NCT06385340
NCT06321003
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06499415